Skip to main navigation
Skip to search
Skip to main content
Prinses Máxima Centrum Home
Nederlands
English
Home
Profiles
Research Groups
Equipment
Research output
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Total pelvic exenteration for primary and recurrent malignancies
F. T.J. Ferenschild
, M. Vermaas
, C. Verhoef
, A. C. Ansink
, W. J. Kirkels
,
A. M.M. Eggermont
, J. H.W. De Wilt
Research output
:
Contribution to journal
›
Article
›
peer-review
166
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Total pelvic exenteration for primary and recurrent malignancies'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Subsequent Malignancies
100%
Primary Malignancy
100%
Total Pelvic Exenteration
100%
Cervical Cancer
75%
Gross Total Resection
75%
Locally Advanced Rectal Cancer
75%
Overall Survival
50%
Local Control
50%
Incomplete Resection
50%
Locally Recurrent Rectal Cancer
50%
Major Complications
25%
Colorectal Cancer
25%
Prostate
25%
Prognostic Factors
25%
Hospitalization
25%
Sarcoma
25%
Neoadjuvant Chemotherapy
25%
Complication Rate
25%
Seminal Vesicle
25%
Bladder
25%
Advanced Tumor
25%
Uterus
25%
Rectum
25%
Pelvic Malignancy
25%
Blood Loss
25%
Surgical Technique
25%
Timing of Surgery
25%
Postoperative Radiotherapy
25%
Minor Complications
25%
Adjacent Organ
25%
Locally Advanced
25%
In-hospital Mortality
25%
Downstaging
25%
Locally Recurrent
25%
Pelvic Cancer
25%
Organ Structure
25%
Recurrent Endometrial Carcinoma
25%
Pelvic Tumor
25%
En Bloc Resection
25%
Genital Organs
25%
Invasive Cervical Cancer
25%
Medicine and Dentistry
Cancer
100%
Surgery
100%
Rectum Cancer
100%
Pelvic Exenteration
100%
Cervical Cancer
66%
Overall Survival
33%
Neoplasm
16%
Prognostic Factor
16%
Bladder
16%
Mortality Rate
16%
Bleeding
16%
Neoadjuvant Chemotherapy
16%
Pelvis
16%
Seminal Vesicle
16%
Surgical Technique
16%
Preoperative Radiotherapy
16%
Hospital Mortality
16%
Pelvis Cancer
16%
Endometrium Carcinoma
16%
Pelvic Tumor
16%
Connective Tissue Cancer
16%